Cerveau Technologies Inc. announced a research collaboration with the NYU Langone Medical Center to support various research projects studying the stages of Alzheimer’s Disease and other Neurodegenerative diseases. These research projects will utilize an investigational imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
As part of the agreement, Cerveau will support various research projects and supply [18F]MK-6240 needed for the initiatives.
According to Professor Mony de Leon from the NYU Langone Medical Center, Department of Psychiatry and Director of the Center for Brain Health, “support from Cerveau nicely bridges the Alzheimer disease work funded by the NIH and the traumatic brain injury studies supported by Cohen Veteran Bioscience. The Cerveau project offers an exciting opportunity to launch clinical and basic studies investigating the spread of tau pathology using PET and the tau imaging agent MK-6240.”
“Cerveau is excited to be working with Dr. de Leon and his colleagues to better understand Tau pathology,” said Rick Hiatt, President of Cerveau Technologies, Inc., “The partnership with NYU Langone Medical Center is another important step forward in our strategy of developing an international network of key collaborators and production sites to enable broad access for scientific research and clinical trial support.”
